{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:41:44Z","timestamp":1768783304431,"version":"3.49.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Acquired retinal diseases such as age-related macular degeneration and diabetic retinopathy rank among the leading causes of blindness and visual loss worldwide. Effective treatments for these conditions are available, but often have a high treatment burden, and poor compliance can lead to disappointing real-world outcomes. Development of new treatment strategies that provide more durable treatment effects could help to address some of these unmet needs. Gene-based therapeutics, pioneered for the treatment of monogenic inherited retinal disease, are being actively investigated as new treatments for acquired retinal disease. There are significant advantages to the application of gene-based therapeutics in acquired retinal disease, including the presence of established therapeutic targets and common pathophysiologic pathways between diseases, the lack of genotype-specificity required, and the larger potential treatment population per therapy. Different gene-based therapeutic strategies have been attempted, including gene augmentation therapy to induce <jats:italic>in vivo<\/jats:italic> expression of therapeutic molecules, and gene editing to knock down genes encoding specific mediators in disease pathways. We highlight the opportunities and unmet clinical needs in acquired retinal disease, review the progress made thus far with current therapeutic strategies and surgical delivery techniques, and discuss limitations and future directions in the field.<\/jats:p>","DOI":"10.3389\/fgene.2021.795010","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T13:05:18Z","timestamp":1638882318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Gene-Based Therapeutics for Acquired Retinal Disease: Opportunities and Progress"],"prefix":"10.3389","volume":"12","author":[{"given":"Tien-En","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beau James","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veluchamy Amutha","family":"Barathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Bo Bo","family":"Tun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeo Sia","family":"Wey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Shih Hsiang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu Yen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodhbir Singh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin Yi Chong","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic Retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"14064","DOI":"10.1038\/mtm.2014.64","article-title":"Multigenic Lentiviral Vectors for Combined and Tissue-specific Expression of miRNA- and Protein-Based Antiangiogenic Factors","volume":"2","author":"Askou","year":"2015","journal-title":"Mol. Ther. - Methods Clin. Development"},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omtn.2019.01.012","article-title":"Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy","volume":"16","author":"Askou","year":"2019","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jgm.2678","article-title":"Reduction of Choroidal Neovascularization in Mice by Adeno-Associated Virus-Delivered Anti-vascular Endothelial Growth Factor Short Hairpin RNA","volume":"14","author":"Askou","year":"2012","journal-title":"J. Gene Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000455277","article-title":"Diabetic Macular Edema","volume":"58","author":"Bandello","year":"2017","journal-title":"Dev. Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00592-012-0449-3","article-title":"Pathophysiology and Treatment of Diabetic Retinopathy","volume":"50","author":"Bandello","year":"2013","journal-title":"Acta Diabetol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/OPTH.S128509","article-title":"Anti-VEGF Treatment of Diabetic Macular Edema in Clinical Practice: Effectiveness and Patterns of Use (ECHO Study Report 1)","volume":"11","author":"Blinder","year":"2017","journal-title":"Opth"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated Virus Antibody Profiles in Newborns, Children, and Adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/hum.2016.117","article-title":"Lentiviral Vector Gene Transfer of Endostatin\/Angiostatin for Macular Degeneration (GEM) Study","volume":"28","author":"Campochiaro","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral Vector-Delivered Pigment Epithelium-Derived Factor for Neovascular Age-Related Macular Degeneration: Results of a Phase I Clinical Trial","volume":"17","author":"Campochiaro","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"B12","article-title":"Suprachoroidal Gene Theraepy for Exudative AMD and Diabetic Retinopathy","author":"Campochiaro","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"B14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/s0039-6257(02)00336-3","article-title":"Gene Therapy for Genetic and Acquired Retinal Diseases","volume":"47","author":"Chaum","year":"2002","journal-title":"Surv. Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40291-018-0377-1","article-title":"Attenuation of Inherited and Acquired Retinal Degeneration Progression with Gene-Based Techniques","volume":"23","author":"Cho","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003267","article-title":"The Impact of Disease Activity on 5 Year Outcomes in Patients Undergoing Treatment for Neovascular Age Related Macular Degeneration","author":"Chong Teo","year":"2021","journal-title":"Retina"},{"key":"B17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the Treatment of Wet AMD: a Summary of Real-World Studies","volume":"30","author":"Chong","year":"2016","journal-title":"Eye"},{"key":"B18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000360466","article-title":"Proliferative Vitreoretinopathy","volume":"54","author":"Claes","year":"2014","journal-title":"Dev. Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000438970","article-title":"Diabetic Retinopathy and Diabetic Macular Edema","volume":"55","author":"Cohen","year":"2016","journal-title":"Dev. Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","article-title":"Gene Therapy in Neovascular Age-Related Macular Degeneration: Three-Year Follow-Up of a Phase 1 Randomized Dose Escalation Trial","volume":"177","author":"Constable","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-Related Macular Degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In Vivo-directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","article-title":"Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration","volume":"39","author":"Davis","year":"2019","journal-title":"RETINA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20554","DOI":"10.1038\/s41598-020-77254-0","article-title":"Topical Delivery of a Small Molecule RUNX1 Transcription Factor Inhibitor for the Treatment of Proliferative Vitreoretinopathy","volume":"10","author":"Delgado-Tirado","year":"2020","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.oret.2019.10.019","article-title":"Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians","volume":"4","author":"Fenner","year":"2020","journal-title":"Ophthalmol. Retina"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global Causes of Blindness and Distance Vision Impairment 1990-2020: a Systematic Review and Meta-Analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"OED.S4878","DOI":"10.4137\/OED.S4878","article-title":"Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration","volume":"2","author":"Garba","year":"2010","journal-title":"Ophthalmol. Eye Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/ICU.0000000000000256","article-title":"Update on Ocular Gene Therapy and Advances in Treatment of Inherited Retinal Diseases and Exudative Macular Degeneration","volume":"27","author":"Garoon","year":"2016","journal-title":"Curr. Opin. Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of Geographic Atrophy in Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-VEGF Agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye"},{"key":"B31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of Geographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.oret.2019.11.011","article-title":"Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmol. Retina"},{"key":"B33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous Injection of AAV2-sFLT01 in Patients with Advanced Neovascular Age-Related Macular Degeneration: a Phase 1, Open-Label Trial","volume":"390","author":"Heier","year":"2017","journal-title":"The Lancet"},{"key":"B34","article-title":"Subretinal Gene Therapy for Exudative AMD","author":"Ho","year":"2021"},{"key":"B35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.omtn.2017.08.016","article-title":"In Vivo Knockout of the Vegfa Gene by Lentiviral Delivery of CRISPR\/Cas9 in Mouse Retinal Pigment Epithelium Cells","volume":"9","author":"Holmgaard","year":"2017","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41467-017-00140-3","article-title":"Genome Editing Abrogates Angiogenesis In Vivo","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamaophthalmol.2017.0837","article-title":"Cost-effectiveness of Intravitreous Ranibizumab Compared with Panretinal Photocoagulation for Proliferative Diabetic Retinopathy","volume":"135","author":"Hutton","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/IIO.0000000000000258","article-title":"Proliferative Vitreoretinopathy: A Review","volume":"59","author":"Idrees","year":"2019","journal-title":"Int. Ophthalmol. Clin."},{"key":"B39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/bit.26031","article-title":"Insight into the Mechanisms of Enhanced Retinal Transduction by the Engineered AAV2 Capsid Variant -7m8","volume":"113","author":"Khabou","year":"2016","journal-title":"Biotechnol. Bioeng."},{"key":"B41","unstructured":"ADVM-022 Intravitreal Gene Therapy for Neovascular AMD - Phase 1 OPTIC Study\n            KhananiA. M.\n          2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In Vivo genome Editing with a Small Cas9 Orthologue Derived from Campylobacter Jejuni","volume":"8","author":"Kim","year":"","journal-title":"Nat. Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1101\/gr.219089.116","article-title":"Genome Surgery Using Cas9 Ribonucleoproteins for the Treatment of Age-Related Macular Degeneration","volume":"27","author":"Kim","year":"","journal-title":"Genome Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am. J. Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and Target-independent Angiogenesis Suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/s41467-018-04175-y","article-title":"CRISPR-LbCpf1 Prevents Choroidal Neovascularization in a Mouse Model of Age-Related Macular Degeneration","volume":"9","author":"Koo","year":"2018","journal-title":"Nat. Commun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody Neutralization Poses a Barrier to Intravitreal Adeno-Associated Viral Vector Gene Delivery to Non-human Primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","article-title":"Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries","volume":"158","author":"Lad","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e102538","DOI":"10.1371\/journal.pone.0102538","article-title":"Transgene Regulation Using the Tetracycline-Inducible TetR-KRAB System after AAV-Mediated Gene Transfer in Rodents and Nonhuman Primates","volume":"9","author":"Le Guiner","year":"2014","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.ymthe.2020.06.029","article-title":"Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update","volume":"28","author":"Lin","year":"2020","journal-title":"Mol. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.ophtha.2016.05.037","article-title":"Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy","volume":"123","author":"Lin","year":"2016","journal-title":"Ophthalmology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral Delivery of Co-packaged Cas9 mRNA and a Vegfa-Targeting Guide RNA Prevents Wet Age-Related Macular Degeneration in Mice","volume":"5","author":"Ling","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"B53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41586-020-2975-4","article-title":"Reprogramming to Recover Youthful Epigenetic Information and Restore Vision","volume":"588","author":"Lu","year":"2020","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world Outcomes in Patients with Neovascular Age-Related Macular Degeneration Treated with Intravitreal Vascular Endothelial Growth Factor Inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"B55","first-page":"574","article-title":"Vascular Endothelial Growth Factor\/vascular Permeability Factor Is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model","volume":"145","author":"Miller","year":"1994","journal-title":"Am. J. Pathol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e0233595","DOI":"10.1371\/journal.pone.0233595","article-title":"Effectiveness and Safety of Ranibizumab 0.5 Mg in Treatment-Na\u00efve Patients with Diabetic Macular Edema: Results from the Real-World Global LUMINOUS Study","volume":"15","author":"Mitchell","year":"2020","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14712598.2017.1356817","article-title":"Gene Therapy for Age-Related Macular Degeneration","volume":"17","author":"Moore","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/hmg\/ddx028","article-title":"Therapeutic Potential of AAV-Mediated MMP-3 Secretion from Corneal Endothelium in Treating Glaucoma","volume":"26","author":"O\u2019Callaghan","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-vision-082114-035532","article-title":"Optogenetic Approaches to Restoring Vision","volume":"1","author":"Pan","year":"2015","journal-title":"Annu. Rev. Vis. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.oret.2020.02.003","article-title":"Aflibercept Reduces Retinal Hemorrhages and Intravitreal Microvascular Abnormalities but Not Venous Beading","volume":"4","author":"Pearce","year":"2020","journal-title":"Ophthalmol. Retina"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e17140","DOI":"10.1371\/journal.pone.0017140","article-title":"Ab-externo AAV-Mediated Gene Delivery to the Suprachoroidal Space Using a 250 Micron Flexible Microcatheter","volume":"6","author":"Peden","year":"2011","journal-title":"PLoS One"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene Therapy with Recombinant Adeno-Associated Vectors for Neovascular Age-Related Macular Degeneration: 1 Year Follow-Up of a Phase 1 Randomised Clinical Trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"The Lancet"},{"key":"B65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ajo.2019.03.006","article-title":"Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration","volume":"204","author":"Rakoczy","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1167\/iovs.17-22494","article-title":"Humoral Immune Response after Intravitreal but Not after Subretinal AAV8 in Primates and Patients","volume":"59","author":"Reichel","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for Neovascular Age-Related Macular Degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and Safety of Voretigene Neparvovec (AAV2-hRPE65v2) in Patients with RPE65 -mediated Inherited Retinal Dystrophy: a Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"390","author":"Russell","year":"2017","journal-title":"The Lancet"},{"key":"B69","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/dme.12119","article-title":"Prevalence of Diabetic Retinopathy in Type 2 Diabetes in Developing and Developed Countries","volume":"30","author":"Ruta","year":"2013","journal-title":"Diabet. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/09286586.2016.1193618","article-title":"Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy","volume":"23","author":"Sabanayagam","year":"2016","journal-title":"Ophthalmic Epidemiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2019.11.010","article-title":"Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration","volume":"127","author":"Sadda","year":"2020","journal-title":"Ophthalmology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial Recovery of Visual Function in a Blind Patient after Optogenetic Therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"18751","DOI":"10.1073\/pnas.0905010106","article-title":"An Essential Role for RPE-Derived Soluble VEGF in the Maintenance of the Choriocapillaris","volume":"106","author":"Saint-Geniez","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/srep17105","article-title":"An Autogenously Regulated Expression System for Gene Therapeutic Ocular Applications","volume":"5","author":"Sochor","year":"2015","journal-title":"Sci. Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","article-title":"Global Epidemiology of Retinal Vein Occlusion: a Systematic Review and Meta-Analysis of Prevalence, Incidence, and Risk Factors","volume":"9","author":"Song","year":"2019","journal-title":"J. Glob. Health"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus Laser Therapy for the Treatment of Very Low Birthweight Infants with Retinopathy of Prematurity (RAINBOW): an Open-Label Randomised Controlled Trial","volume":"394","author":"Stahl","year":"2019","journal-title":"The Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.ymthe.2005.12.001","article-title":"Long-term Doxycycline-Regulated Transgene Expression in the Retina of Nonhuman Primates Following Subretinal Injection of Recombinant AAV Vectors","volume":"13","author":"Stieger","year":"2006","journal-title":"Mol. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ymthe.2016.10.008","article-title":"Improved Intravitreal AAV-Mediated Inner Retinal Gene Transduction after Surgical Internal Limiting Membrane Peeling in Cynomolgus Monkeys","volume":"25","author":"Takahashi","year":"2017","journal-title":"Mol. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/13816810.2018.1495745","article-title":"Gene Therapy in Inherited Retinal Degenerative Diseases, a Review","volume":"39","author":"Takahashi","year":"2018","journal-title":"Ophthalmic Genet."},{"key":"B81","doi-asserted-by":"publisher","first-page":"bjophthalmol","DOI":"10.1136\/bjophthalmol-2021-319365","article-title":"Artificial Intelligence for Diagnosis of Inherited Retinal Disease: an Exciting Opportunity and One Step Forward","author":"Tan","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1167\/iovs.18-24333","article-title":"Surgical Removal of Internal Limiting Membrane and Layering of AAV Vector on the Retina under Air Enhances Gene Transfection in a Nonhuman Primate","volume":"59","author":"Teo","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.2147\/OPTH.S281501","article-title":"Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)","volume":"14","author":"Van Aken","year":"2020","journal-title":"Opth"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi Therapeutic and its Innovative Biotechnological Evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"B86","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/APO.0000000000000267","article-title":"The War on Diabetic Retinopathy: Where Are We Now?","volume":"8","author":"Wong","year":"2019","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on Diabetic Eye Care","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global Prevalence of Age-Related Macular Degeneration and Disease burden Projection for 2020 and 2040: a Systematic Review and Meta-Analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"B89","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/APO.0000000000000362","article-title":"Creating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases","volume":"10","author":"Xu","year":"2021","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"key":"B90","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global Prevalence and Major Risk Factors of Diabetic Retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"B91","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target Effects in CRISPR\/Cas9-mediated Genome Engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. - Nucleic Acids"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.795010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T13:05:26Z","timestamp":1638882326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.795010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":92,"alternative-id":["10.3389\/fgene.2021.795010"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.795010","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"article-number":"795010"}}